unknown
Stage
2
Investors
About
Glycostem Therapeutics develops allogeneic off-the-shelf Natural Killer (NK) cell therapies derived from umbilical cord blood stem cells to treat various cancers including acute myeloid leukemia and multiple myeloma.
Explore Glycostem Therapeutics B.V's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.